| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,695,702 ) |
| | 2024 | 2024 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R44HL156334 | Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier | 001 | 3 | NIH | 7/27/2024 | $807,795 |
| | 2024 | 2024 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R44HL154864 | Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | 003 | 3 | NIH | 8/7/2024 | $887,907 |
| | 2024 | 2023 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R44HL154864 | Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | 002 | 2 | NIH | 8/1/2024 | $0 |
| | 2024 | 2023 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R44HL154864 | Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | 001 | 2 | NIH | 11/9/2023 | $976,740 |
| | 2024 | 2023 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R44HL154864 | Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | 000 | 2 | NIH | 11/3/2023 | -$976,740 |
| | 2024 | 2023 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R44HL156334 | Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier | 000 | 2 | NIH | 10/24/2023 | $12 |
| | 2024 | 2021 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL156334 | Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier | 000 | 1 | NIH | 10/24/2023 | -$12 |
| | 2024 | 2020 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL150961 | Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease | 000 | 1 | NIH | 12/6/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,722,361 ) |
| | 2023 | 2023 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R44HL156334 | Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier | 000 | 2 | NIH | 6/26/2023 | $745,621 |
| | 2023 | 2023 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R44HL154864 | Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | 000 | 2 | NIH | 8/23/2023 | $976,740 |
|
| Issue Date FY: 2022 ( Subtotal = -$8 ) |
| | 2022 | 2021 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL156334 | Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier | 000 | 1 | NIH | 11/18/2021 | $0 |
| | 2022 | 2020 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL154864 | Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | 000 | 1 | NIH | 8/18/2022 | -$8 |
| | 2022 | 2020 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL150961 | Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease | 000 | 1 | NIH | 2/15/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $298,412 ) |
| | 2021 | 2021 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL156334 | Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier | 000 | 1 | NIH | 12/28/2020 | $298,412 |
| | 2021 | 2020 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL154864 | Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | 000 | 1 | NIH | 3/2/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $599,962 ) |
| | 2020 | 2020 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL154864 | Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy | 000 | 1 | NIH | 8/10/2020 | $300,000 |
| | 2020 | 2020 | ILLEXCOR THERAPEUTICS LLC | 800 E LEIGH ST STE 19 | RICHMOND | VA | 23219-1599 | RICHMOND CITY | USA | R43HL150961 | Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease | 000 | 1 | NIH | 2/14/2020 | $299,962 |
|
|
